2014-2015 Webinars



Products

World Transplant Congress 2014: Clinical Highlights

Preview Available

World Transplant Congress 2014: Clinical Highlights


Whether you missed the World Transplant Congress or simply did not have time to catch all of the sessions, attend this webinar and get the important clinical highlights from the meeting.

Speaker(s):
Standard: $25.00

Kidney Allocation System Changes: Strategies to  Improve Recipient Readiness and Reduce Disparities

Preview Available

Kidney Allocation System Changes: Strategies to Improve Recipient Readiness and Reduce Disparities


Speaker(s):
Standard: $25.00

Vaccine Updates in SOT: What's New, What's Standard of Care?

Preview Available

Vaccine Updates in SOT: What's New, What's Standard of Care?


Transplant clinicians strive to prevent infection, and vaccination provides an opportunity to expand this effort. The current recommendations for vaccination, innovative research, and opportunity for advancing these efforts will be discussed.

Objectives:

  • Explore current pre- and post-transplant vaccination recommendations for pediatric and adult transplant candidates/recipients.
  • Appraise recent vaccination studies in transplantation with a focus on live-vaccines and more recently approved vaccinations.
  • Identify new opportunities for vaccination in transplantation that are emerging.

Speaker(s):
Standard: $25.00

Treatment of Antibody-mediated Rejection in Thoracic Transplants

Preview Available

Treatment of Antibody-mediated Rejection in Thoracic Transplants


Explore the diagnosis and treatment strategies, including the role of desensitization, in lung and heart transplantation. Discuss challenges and avenues for further research and investigation.

Objectives:
  • Describe how to diagnose antibody-mediated rejection in lung and heart transplant recipients.
  • Evaluate and review the desensitization strategies currently used in lung and heart transplant candidates and recipients.
  • Summarize the different treatment approaches for treatment of antibody-mediated rejection.

Speaker(s): Speaker(s):
  • Matt Morrell, MD, University of Pittsburgh School of Medicine
Standard: $25.00

Multiorgan Transplantation: One Organ Too Many?

Preview Available

Multiorgan Transplantation: One Organ Too Many?


The debate over the appropriateness of combined liver and kidney transplants was stoked by the introduction of the MELD system and continues today as the waiting list for kidney alone candidates continues to grow. This education session will feature a review of the current data and experience with combined liver and kidney transplantation and will explore the controversial topics of when to allocate a kidney to candidates with liver failure and acute kidney injury.

Objectives:

  • Describe the current policies at UNOS regarding simultaneous liver-kidney allocation
  • Explain data related to outcomes for liver transplant candidates with kidney injury
  • Summarize arguments and ethics surrounding the development of new allocation policies for simultaneous liver-kidney transplantation

Speaker(s):
Standard: $25.00

Medically Complex Living Donors: Candidacy, Care, and Informed Consent

Preview Available

Medically Complex Living Donors: Candidacy, Care, and Informed Consent


The long-term acceptance of living donor transplantation has been based on a combination of excellent recipient outcomes and belief that in actuarial terms, there is no increased risk of living with one kidney. However, recent studies have raised controversy and concerns regarding the long-term risks of CKD in kidney donors. How do we interpret these findings? How do we evaluate and when do we clear donors with pre-existing medical conditions like hypertension, obesity, kidney stones, etc., and convey divergent opinions to patients? Comprehensive donor consent remains at the core of this process. Though perceived as challenging existing assumptions, the disclosure of new data will enable a better understanding of the risks so that potential living donors can make a more meaningful, informed decision.

Objectives:

  • Distinguish between “low risk donors” and medically complex living donors.
  • Evaluate the meanings of new studies regarding donor risk.
  • Refine the current informed consent process in light of the evolving data.

Speaker(s):
  • David Serur, MD, NYP-Well Cornell and Regosin Institute
Speaker(s):
Standard: $25.00

Hepatitis C Treatment in Non-liver Solid Organ Transplant Recipients

Preview Available

Hepatitis C Treatment in Non-liver Solid Organ Transplant Recipients


The diagnosis of chronic hepatitis C has been considered a relative or absolute contraindication for non-liver transplantation in the past, due to concerns of liver disease progression post-transplantation and a lack of safe and effective therapies. The recent availability of interferon-free, all-oral, antiviral drug combinations to treat of chronic hepatitis C provides an opportunity to revise management algorithms to optimize the care of non-liver transplant candidates and recipients.

Objectives:

  • Describe the components of the new HCV all-oral combinations, the role of ribavirin, and anticipated rates of HCV eradication with treatment
  • Summarize the safety data of new HCV therapies as it pertains to non-liver transplant candidates and recipients, including key drug-drug interactions (HCV antivirals and immunosuppressive drugs)
  • Evaluate the pros and cons of HCV treatment pre versus post-transplantation, including considerations related to use of anti-HCV positive donors

Speaker(s):
Standard: $25.00

Monitoring the Alloresponse Before and After Transplantation

Preview Available

Monitoring the Alloresponse Before and After Transplantation


The goal of this webinar is to describe the available data on pre- and post-transplant immune monitoring and how incorporating specific tests may help us diagnose, predict, and better treat our transplant recipients.

Objectives:

  • Summarize the current most promising and best tested urine and peripheral blood, molecular, and cellular assays available for risk assessment following transplantation
  • Detail the utility, pitfalls and limitations of currently available assays
  • Propose future directions and trial designs required to develop and validate immune monitoring tools for clinical use

Speaker(s):
Standard: $25.00

Cytomegalovirus: Prevention, Therapy, Immunity

Preview Available

Cytomegalovirus: Prevention, Therapy, Immunity


Dr. Kotton will describe the importance of prevention, and the various methods of preventing CMV, including; universal prophylaxis, preemptive therapy, and a hybrid approach, along with the merits and downfalls of each approach. Dr. Razonable will review the current recommendations for the treatment of cytomegalovirus infection and disease in transplant recipients, and discuss antiviral drugs in the pipeline that may be useful for the treatment of drug-resistant infections. Dr. Humar will explain how measurements of host immune response to CMV can be used to predict the risk of CMV reactivation in different settings, and how prevention and treatment strategies might be refined with the use of immune monitoring tools.

Objectives:

  • Discuss the importance of CMV prevention, along with the various approaches used for optimal prevention
  • Explain the standard treatment for CMV infection and disease in transplant recipients and discuss novel antiviral drugs
  • Describe the potential for using immune monitoring tools to refine and improve prevention and treatment strategies

Speaker(s): Speaker(s):
Standard: $25.00

Update on Hepatitis C Eradication Including Renal Clearance and Dosing and Important DDI Highlights

Preview Available

Update on Hepatitis C Eradication Including Renal Clearance and Dosing and Important DDI Highlights


This webinar is designed to focus on emerging therapies for HCV in transplant patients with specific attention to drug-drug interactions and limitations in patients with renal disease.

Objectives:

  • Define current strategies for HCV treatment in the post transplant recipient
  • Describe the limitations of current drug therapy in patients with renal disease
  • Explain relevant drug-drug interactions of antiviral therapies with transplant medications

Speaker(s): Speaker(s):
Standard: $25.00
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content